ଲାନରିଓଟାଇଡ

ଲାନରିଓଟାଇଡ
Clinical data
Pronunciation	lan ree' oh tide
Trade names	Somatuline
Synonyms	Lanreotide acetate
AHFS/Drugs.com	monograph
data	US FDA: Lanreotide;
Pregnancy; category	AU: C ; US: C (Risk not ruled out) ; ;
Routes of; administration	Intramuscular, subcutaneous
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	Approximately 80%
Protein binding	78%
Metabolism	In GI tract
Elimination half-life	2 hours (immediate release); 5 days (sustained release)
Excretion	Mostly biliary
Identifiers
	IUPAC name 3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide (2->7)-disulfide;
ECHA InfoCard	100.215.992
Chemical and physical data
Formula	C54H69N11O10S2
Molar mass	1096.33 g/mol; 1156.380 g/mol (acetate)
3D model (JSmol)	Interactive image;
	SMILES C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)Cc2c[nH]c3c2cccc3)Cc4ccc(cc4)O)NC(=O)[C@@H](Cc5ccc6ccccc6c5)N)O;
	InChI InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)/t30-,38-,40+,41+,42-,43+,44+,45+,46+/m1/s1 ; Key:PUDHBTGHUJUUFI-SCTWWAJVSA-N ;
(verify)

ଲାନରିଓଟାଇଡ (ଇଂରାଜୀ ଭାଷାରେ Lanreotide), ସୋମାଟୁଲିନ୍ ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଆକ୍ରୋମେଗାଲି, ନ୍ୟୁରୋଏଣ୍ଡୋକ୍ରାଇନ ଅର୍ବୁଦ ଯେପରିକି କାରସିନଏଡ ଏବଂ ଥାଇରଏଡ ଅର୍ବୁଦ ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୨] ଆକ୍ରୋମାଗାଲିରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସା ଫଳପ୍ରଦ ହୁଏ ନାହିଁ ।^[୩] ଚର୍ମ ତଳେ କିମ୍ବା ମାଂସପେଶୀରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେଏହା ଦିଆଯାଏ । ^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ପେଟ ଯନ୍ତ୍ରଣା, ଅଇ, ପାକସ୍ଥଳୀ ଯନ୍ତ୍ରଣା, ଗଣ୍ଠି ଯନ୍ତ୍ରଣା ଏବଂ ଇଞ୍ଜେକସନ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ଅନ୍ଥୋଇପାରେ ।^[୩] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଗ୍ନାଶୟ ପ୍ରଦାହ, ଉଚ୍ଚ ରକ୍ତ ଶର୍କରା, କମ୍ ରକ୍ତ ଶର୍କରା ଏବଂ ଯକୃତ ସମସ୍ୟା ହୋଇପାରେ | ^[୧] ଏହା ଏକ ସୋମାଟୋଷ୍ଟାଟିନ୍ ଆନାଲଗ ଯାହା ବିକାଶ (ଗ୍ରୋଥ) ହରମୋନ, ଇନସୁଲିନ୍ ଏବଂ ଗ୍ଲୁକାଗନ ସ୍ତର ହ୍ରାସ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୨] ^[୧]

୨୦୦୭ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଲାନରିଓଟାଇଡ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ମାସକୁ ୬୦ ମିଗ୍ରା ହିସାବରେ ପ୍ରାୟ ୫୫୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶି ପିଛା ଖର୍ଚ୍ଚ ପ୍ରାୟ ୬,୧୦୦ ଡଲାର । ^[୪]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Lanreotide". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 20 November 2021. Retrieved 20 November 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 993. ISBN 978-0857114105.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Lanreotide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 24 January 2021. Retrieved 20 November 2021.
↑ "Somatuline Depot Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 17 April 2021. Retrieved 20 November 2021.

[Liv2021-1] ୧.୦ ^୧.୧ ^୧.୨ "Lanreotide". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 20 November 2021. Retrieved 20 November 2021.

[BNF81-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 993. ISBN 978-0857114105.

[AHFS2021-3] ୩.୦ ^୩.୧ ^୩.୨ "Lanreotide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 24 January 2021. Retrieved 20 November 2021.

[4] "Somatuline Depot Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 17 April 2021. Retrieved 20 November 2021.

[୨]

[୩]

[୧]

[୪]

Clinical data

Pronunciation	lan ree' oh tide^[୧]
Trade names	Somatuline
Synonyms	Lanreotide acetate
AHFS/Drugs.com	monograph
data	US FDA: Lanreotide
Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	Intramuscular, subcutaneous
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	Approximately 80%
Protein binding	78%
Metabolism	In GI tract
Elimination half-life	2 hours (immediate release) 5 days (sustained release)
Excretion	Mostly biliary
Identifiers
IUPAC name 3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide (2->7)-disulfide
ECHA InfoCard	100.215.992
Chemical and physical data
Formula	C₅₄H₆₉N₁₁O₁₀S₂
Molar mass	1096.33 g/mol 1156.380 g/mol (acetate)
3D model (JSmol)	Interactive image
SMILES C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)Cc2c[nH]c3c2cccc3)Cc4ccc(cc4)O)NC(=O)[C@@H](Cc5ccc6ccccc6c5)N)O
InChI InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)/t30-,38-,40+,41+,42-,43+,44+,45+,46+/m1/s1^N Key:PUDHBTGHUJUUFI-SCTWWAJVSA-N^N
(verify)